SAKAR2025-04-012025-06-30SAKAR2025-06-30SAKAR2025-04-012025-06-30in-capmkt:OtherExpenses1MemberSAKAR2025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1SAKAR2025-06-30Statement1SAKAR2025-04-012025-06-30Statement1SAKAR2025-06-30StatementDynamic1I1Statement1SAKAR2025-06-30StatementDynamic1I2Statement1iso4217:INRxbrli:pureiso4217:INRxbrli:shares000000SAKARNOTLISTEDINE732S01012Sakar Healthcare LimitedMain BoardEquity2025-04-012026-03-312025-07-252025-07-21INRLakhsQuarterlyFirst quarterSingle segmentPharmaceuticals2025-07-2511:30:002025-07-2512:10:00true1falseAs on Date Not Applicable2025-04-012025-06-30UnauditedStandalone5273620003939000531301000287573000019510007549600021426000557230003528400047745300053848000053848000071350007135000046713000000046713000-26700046446000222499000102.112.11002.112.11For Quarter ended 30th June 2025 the Current tax is Rs. 90.29 lacs and MAT Credit Entitlement is Rs. 90.29 lacs hence the net effect is NIL <BR> <BR> 1 The Company is operating only in one segment Hence segment reporting is not given. <BR> 2. The above financial results have been prepared in accordance with the Companies Indian Accounting Standards Rules 2015 Ind AS as amended prescribed under Section 133 of the Companies Act 2013 read with relevant rules issued thereunder. <BR> 3. The Company has a wholly owned subsidiary vis Sakar Oncology Private Limited. Other than this the Company does not have any subsidiary or associate. <BR> 4. Provision for taxation deferred taxation if any will be made at the year end. <BR> 5. Figures wherever required are regrouped or rearranged. <BR> 6. The above results have been reviewed by audit committee and approved by Board of Directors of Company at its meeting held on 25th July 2025. <BR> 7. The Company has allotted 300000 Equity Shares to NonPromoters on conversion of Convertible Warrants in to Equity on Preferential Basis on 17th June 2025Other Expenses35284000Re measurement gains or losses on defined benefit plans-370000-370000-1030000-267000Preferential Issues2025-06-17864000002025-06-30falsefalseSANJAY SHAHManaging DirectorAHMEDABAD2025-07-25Repayment prepayment of all or a portion of certain borrowings from State Bank of India availed by our CompanyNA154650000154650000Capital expenditure for Procurement of Lipid Complex Injections Machinery and Equipments Utilities with electrification for Oncology unitNA7093500001845600052479000